van Straaten H L, Groote M E, Oudesluys-Murphy A M
University of Amsterdam, Department of Neonatology, The Netherlands.
Eur J Pediatr. 1996 Aug;155(8):702-5. doi: 10.1007/BF01957157.
An automated auditory brainstem response (ABR) method-the ALGO-1 Plus- has been developed for hearing screening in healthy neonates. The aim of this study was to test the validity of this automated ABR screening method in at-risk neonates in a neonatal intensive care unit. Two hundred and fifty at-risk neonates were selected for screening according to the criteria of the American Joint Commerce on Infant Hearing. All 250 neonates were screened with the ALGO-1 Plus for bilateral hearing loss. When two consecutive screenings pointed to bilateral hearing loss ("refer") further audiological investigations were performed and where necessary therapeutic measures were taken. All children who "passed" the screening unilateral or bilateral enrolled in a nationwide behavioural screening programme at the age of 9 months as well as in a 6-monthly follow up programme documenting speech and language development. A total of 245 (98%) neonates passed the ALGO-1 screening, 230 (92%) at the first attempt and 15 (6%) at the second attempt. Five (2%) were referred with bilateral hearing loss. One of these died of congenital rubella shortly after screening and bilateral congenital hearing loss of > 35 dB was confirmed in the other 4. None of the infants who passed the screening were discovered to have moderate to severe bilateral hearing loss (> 40 dB) with behavioural screening (n = 183/233) or at follow up (n = 233/233). In this study, all at-risk neonates with bilateral congenital hearing loss were detected with ALGO-1 Plus screening. No false-negatives were discovered.
The ALGO-1 Plus infant hearing screener can be used as a valid automated ABR-screener to detect hearing loss in at-risk neonates in a neonatal intensive care setting.
已开发出一种用于健康新生儿听力筛查的自动听性脑干反应（ABR）方法——ALGO-1 Plus。本研究的目的是在新生儿重症监护病房中测试这种自动ABR筛查方法对高危新生儿的有效性。根据美国婴儿听力联合委员会的标准，选取了250名高危新生儿进行筛查。所有250名新生儿均使用ALGO-1 Plus进行双侧听力损失筛查。当连续两次筛查提示双侧听力损失（“转诊”）时，进行进一步的听力学检查，并在必要时采取治疗措施。所有单侧或双侧“通过”筛查的儿童在9个月大时参加了一项全国性的行为筛查计划，并参加了一项记录言语和语言发育的半年随访计划。共有245名（98%）新生儿通过了ALGO-1筛查，其中230名（92%）在首次筛查时通过，15名（6%）在第二次筛查时通过。5名（2%）因双侧听力损失被转诊。其中1名在筛查后不久死于先天性风疹，另外4名被确诊为双侧先天性听力损失>35 dB。在行为筛查（n = 183/233）或随访（n = 233/233）中，通过筛查的婴儿均未被发现有中度至重度双侧听力损失（>40 dB）。在本研究中，所有双侧先天性听力损失的高危新生儿均通过ALGO-1 Plus筛查被检测出来。未发现假阴性结果。
ALGO-1 Plus婴儿听力筛查仪可作为一种有效的自动ABR筛查仪，用于在新生儿重症监护环境中检测高危新生儿的听力损失。
